Rebel urinary tract infection (UTI) causes serious tasks, causing sustainable discomfort, frequent treatment, and an increase in concerns of antibiotics resistance.
SEQUOIA vaccine, a US -based bio -pharmaceutical company, has developed a new approach to prevent recurrence UTI with FIMCH vaccine, targets important bacterial ingredients to reduce immunity and reduce infection recurrence. Masu.
Fimch vaccine stimulates the immune system and produces antibodies against Fimch pill, which is an important protein structure of colonalcactered bacteria, the most common pathogen in urinary tract infection (UTI). These pillars can adhere to the mucous membrane tissue on the bladder wall. This is an important step to start infection.
When a Fimch vaccine is administered, it causes an immune response that generates a specific antibody for Fimch proteins. These antibodies bind to the piri and prevent bacteria from adhering to the lining of the bladder. By blocking this adhesion, vaccines reduce bacterial colonies, reduce the potential of recurrent infections, and provide positive defense against UTI.
Fimch vaccine clinical test
In the phase 1 test, Sequois Wakuccine’s Fimch vaccine showed promising results for healthy volunteers and recurrent UTI patients. Vaccines have triggered a robust immune response, creating antibodies targeting Fimchipiri in the majority of the test participants.
The test showed that vaccines were highly familiar and had no serious adverse effects. Participants with recurrent UTI have experienced a decrease in UTI frequency, suggesting that vaccines effectively hinder bacteria glue on the bladder wall. These early discoveries suggest that FIMCH vaccine may effectively prevent recurrent urinary tract infections by blocking the adhesion of bacteria in the bladder mucosal tissue. We will build the basics of development and large -scale research.
Expansion of access to highly risky patients
In a compassionate usage environment, the Fimch vaccine of Sequoia Wakucin was administered to patients who were at a high risk of antibiotics -resistant infection that needed to be treated by intravenous carbapenem. The survey shows that vaccines use these high -risk patients to reduce the frequency of recurrent urinary tract UTI. These results suggest that FIMCH vaccine can complement existing treatments, especially in the management of infectious diseases that are particularly resistant to conventional antibiotics.
Future direction
FIMCH vaccine, which targets FIMH Adhin in Ecinosis, has a major promise to prevent various infections beyond UTI, such as preventing sepsis and pneumonia. In addition, Escherichia coli is known to be the cause of patients in the catheter or patients with chronic symptoms such as diabetes and cancer. The vaccines of these groups may help reduce the need for long -term antibiotics. This is important for fighting antibacterial drug resistance.
reference
Eldridge and others. December 16, 2020; 17 (5): 1262-1270.
https://doi.org/10.1080/21645515.2020.1834807 Perer et al. 2024: https: //doi.org/10.3389/fimmu.2024.1359738
This article is also published in the 21st edition of Quarterly Publication.
Source link
